Standout Papers

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemo... 2002 2026 2010 2018 546
  1. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. (2002)
    Reginald V. Lord, Jan Brabender et al. PubMed

Immediate Impact

1 by Nobel laureates 9 from Science/Nature 71 standout
Sub-graph 1 of 19

Citing Papers

Fluorescent Probes for Disease Diagnosis
2024 Standout
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
2023 Standout
10 intermediate papers

Works of F. Cardenal being referenced

3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
2015
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
F. Cardenal 620 579 17 409 26 930
Elisa Chiadini 456 489 17 227 28 785
Shinnosuke Ikemura 473 471 27 489 45 932
Satoshi Yoda 647 481 23 635 26 1.1k
L Pyle 351 293 23 435 18 796
S. Srinivas 512 278 27 403 37 794
Tiffany G. Huynh 560 748 25 374 20 1.2k
Annick Haller 604 511 37 464 22 1.1k
Carmen Nuzzo 309 474 23 396 30 990
Susan Schumer 333 413 27 501 17 1.1k
Tingsheng Peng 458 319 12 597 28 1.1k

All Works

Loading papers...

Rankless by CCL
2026